|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
PHARMACOKINETICS AND PHARMACODYNAMICS |
From the Department of Physiology, University of Science and Technology, School of Medical Sciences (T. Agbenyega) and Departments of Child Health and Medicine, Komfo-Anokye Teaching Hospital (T. Agbenyega, G. Bedu-Addo, D. Ansong, A. Owusu-Ofori), Kumasi, Ghana; Department of Infectious Diseases, St. George's Hospital Medical School, Cranmer Terrace, London, United Kingdom (T. Planche, S. Krishna); Department of Pharmaceutics, College of Pharmacy, University of Florida (V. A. Bhattaram, N. V. Nagaraja, H. Derendorf); Department of Medicine (Division of Endocrinology and Metabolism), College of Medicine, University of Florida (A. L. Shroads, G. N. Henderson, P. W. Stacpoole); Department of Statistics (A. D. Hutson) and Department of Biochemistry and Molecular Biology (P. W. Stacpoole), College of Medicine, University of Florida.
The authors conducted a randomized, double-blind, placebo-controlled trial of intravenous dichloroacetate (DCA) for the purpose of treating lactic acidosis in 124 West African children with severe Plasmodium falciparum malaria. Lactic acidosis independently predicts mortality in severe malaria, and DCA stimulates the oxidative removal of lactate in vivo. A single infusion of 50 mg/kg DCA was well tolerated. When administered at the same time as a dose of intravenous quinine, DCA significantly increased the initial rate and magnitude of fall in blood lactate levels and did not interfere with the plasma kinetics of quinine. The authors developed a novel population pharmacokinetic-pharmacodynamic indirect-response model for DCA that incorporated characteristics associated with disease reversal. The model describes the complex relationships among antimalarial treatment procedures, plasma DCA concentrations, and the drug's lactate-lowering effect. DCA significantly reduces the concentration of blood lactate, an independent predictor of mortality in malaria. Its prospective evaluation in affecting mortality in this disorder appears warranted.
Key Words: Dichloroacetate malaria lactic acidosis population pharmacokinetics pharmacodynamics
Address for reprints: Dr. Peter Stacpoole, Box 100226, JHMHC, Gainesville, FL 32610-0226.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
N. Day and A. M. Dondorp The Management of Patients with Severe Malaria Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 29 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Griffith, L. S. Lewis, S. Mali, and M. E. Parise Treatment of Malaria in the United States: A Systematic Review JAMA, May 23, 2007; 297(20): 2264 - 2277. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jia, B. Coats, M. Chadha, B. Frentzen, J. Perez-Rodriguez, P. A. Chadik, R. A. Yost, G. N. Henderson, and P. W. Stacpoole Human Kinetics of Orally and Intravenously Administered Low-Dose 1,2-13C-Dichloroacetate. J. Clin. Pharmacol., December 1, 2006; 46(12): 1449 - 1459. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Stacpoole, N. V. Nagaraja, and A. D. Hutson Efficacy of Dichloroacetate as a Lactate-Lowering Drug J. Clin. Pharmacol., July 1, 2003; 43(7): 683 - 691. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |